Femasys (FEMY) Competitors

$0.44 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$0.49 +0.05 (+11.42%)

As of 05/22/2026 07:59 PM Eastern

FEMY vs. SLNO, SKIN, SPAI, STIM, and MDAI

Should you buy Femasys stock or one of its competitors? MarketBeat compares Femasys with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Femasys include Soleno Therapeutics (SLNO), Beauty Health (SKIN), Safe Pro Group (SPAI), Neuronetics (STIM), and Spectral AI (MDAI). These companies are all part of the "medical equipment" industry.

How does Femasys compare to Soleno Therapeutics?

Soleno Therapeutics (NASDAQ:SLNO) and Femasys (NASDAQ:FEMY) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends.

Soleno Therapeutics has a beta of -2.22, indicating that its stock price is 322% less volatile than the broader market. Comparatively, Femasys has a beta of -2.26, indicating that its stock price is 326% less volatile than the broader market.

In the previous week, Soleno Therapeutics and Soleno Therapeutics both had 2 articles in the media. Soleno Therapeutics' average media sentiment score of 0.00 equaled Femasys'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Soleno Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Femasys	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Soleno Therapeutics has a net margin of 33.70% compared to Femasys' net margin of -521.97%. Soleno Therapeutics' return on equity of 22.85% beat Femasys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Soleno Therapeutics	33.70%	22.85%	18.25%
Femasys	-521.97%	-258.08%	-73.72%

97.4% of Soleno Therapeutics shares are owned by institutional investors. Comparatively, 65.3% of Femasys shares are owned by institutional investors. 6.4% of Soleno Therapeutics shares are owned by insiders. Comparatively, 7.6% of Femasys shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Soleno Therapeutics presently has a consensus price target of $76.67, indicating a potential upside of 44.63%. Femasys has a consensus price target of $5.33, indicating a potential upside of 1,117.66%. Given Femasys' stronger consensus rating and higher possible upside, analysts clearly believe Femasys is more favorable than Soleno Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Soleno Therapeutics	2 Sell rating(s)	8 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.08
Femasys	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Soleno Therapeutics has higher revenue and earnings than Femasys. Femasys is trading at a lower price-to-earnings ratio than Soleno Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Soleno Therapeutics	$285.01M	9.69	$20.89M	$1.77	29.95
Femasys	$2.29M	11.55	-$18.63M	-$0.27	N/A

Summary

Soleno Therapeutics beats Femasys on 9 of the 13 factors compared between the two stocks.

How does Femasys compare to Beauty Health?

Femasys (NASDAQ:FEMY) and Beauty Health (NASDAQ:SKIN) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership, media sentiment and risk.

Femasys presently has a consensus target price of $5.33, suggesting a potential upside of 1,117.66%. Beauty Health has a consensus target price of $2.02, suggesting a potential upside of 193.73%. Given Femasys' stronger consensus rating and higher probable upside, equities analysts plainly believe Femasys is more favorable than Beauty Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Femasys	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Beauty Health	1 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Beauty Health had 14 more articles in the media than Femasys. MarketBeat recorded 16 mentions for Beauty Health and 2 mentions for Femasys. Beauty Health's average media sentiment score of 0.90 beat Femasys' score of 0.00 indicating that Beauty Health is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Femasys	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Beauty Health	10 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Beauty Health has a net margin of -2.03% compared to Femasys' net margin of -521.97%. Beauty Health's return on equity of -9.38% beat Femasys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Femasys	-521.97%	-258.08%	-73.72%
Beauty Health	-2.03%	-9.38%	-1.21%

65.3% of Femasys shares are owned by institutional investors. Comparatively, 93.3% of Beauty Health shares are owned by institutional investors. 7.6% of Femasys shares are owned by insiders. Comparatively, 40.3% of Beauty Health shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Beauty Health has higher revenue and earnings than Femasys. Beauty Health is trading at a lower price-to-earnings ratio than Femasys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Femasys	$2.29M	11.55	-$18.63M	-$0.27	N/A
Beauty Health	$300.80M	0.30	-$9.52M	-$0.17	N/A

Femasys has a beta of -2.26, meaning that its share price is 326% less volatile than the broader market. Comparatively, Beauty Health has a beta of 1.12, meaning that its share price is 12% more volatile than the broader market.

Summary

Beauty Health beats Femasys on 11 of the 16 factors compared between the two stocks.

How does Femasys compare to Safe Pro Group?

Safe Pro Group (NASDAQ:SPAI) and Femasys (NASDAQ:FEMY) are both small-cap medical equipment companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk.

Femasys has a net margin of -521.97% compared to Safe Pro Group's net margin of -800.91%. Safe Pro Group's return on equity of -119.17% beat Femasys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Safe Pro Group	-800.91%	-119.17%	-107.17%
Femasys	-521.97%	-258.08%	-73.72%

Safe Pro Group currently has a consensus target price of $10.00, suggesting a potential upside of 136.41%. Femasys has a consensus target price of $5.33, suggesting a potential upside of 1,117.66%. Given Femasys' higher possible upside, analysts plainly believe Femasys is more favorable than Safe Pro Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Safe Pro Group	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.60
Femasys	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

65.3% of Femasys shares are held by institutional investors. 54.8% of Safe Pro Group shares are held by company insiders. Comparatively, 7.6% of Femasys shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Safe Pro Group has higher earnings, but lower revenue than Femasys. Safe Pro Group is trading at a lower price-to-earnings ratio than Femasys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Safe Pro Group	$610K	144.86	-$14.32M	-$0.71	N/A
Femasys	$2.29M	11.55	-$18.63M	-$0.27	N/A

In the previous week, Safe Pro Group had 13 more articles in the media than Femasys. MarketBeat recorded 15 mentions for Safe Pro Group and 2 mentions for Femasys. Safe Pro Group's average media sentiment score of 0.43 beat Femasys' score of 0.00 indicating that Safe Pro Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Safe Pro Group	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral
Femasys	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Safe Pro Group has a beta of 3, meaning that its stock price is 200% more volatile than the broader market. Comparatively, Femasys has a beta of -2.26, meaning that its stock price is 326% less volatile than the broader market.

Summary

Safe Pro Group beats Femasys on 9 of the 17 factors compared between the two stocks.

How does Femasys compare to Neuronetics?

Neuronetics (NASDAQ:STIM) and Femasys (NASDAQ:FEMY) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, risk, dividends, valuation, institutional ownership, profitability, earnings and analyst recommendations.

Neuronetics has a beta of 1.13, suggesting that its stock price is 13% more volatile than the broader market. Comparatively, Femasys has a beta of -2.26, suggesting that its stock price is 326% less volatile than the broader market.

Neuronetics has a net margin of -24.48% compared to Femasys' net margin of -521.97%. Neuronetics' return on equity of -139.83% beat Femasys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neuronetics	-24.48%	-139.83%	-27.13%
Femasys	-521.97%	-258.08%	-73.72%

Femasys has lower revenue, but higher earnings than Neuronetics. Neuronetics is trading at a lower price-to-earnings ratio than Femasys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neuronetics	$149.16M	0.56	-$39M	-$0.54	N/A
Femasys	$2.29M	11.55	-$18.63M	-$0.27	N/A

Neuronetics presently has a consensus price target of $3.00, indicating a potential upside of 150.00%. Femasys has a consensus price target of $5.33, indicating a potential upside of 1,117.66%. Given Femasys' stronger consensus rating and higher probable upside, analysts plainly believe Femasys is more favorable than Neuronetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neuronetics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Femasys	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

53.6% of Neuronetics shares are owned by institutional investors. Comparatively, 65.3% of Femasys shares are owned by institutional investors. 8.4% of Neuronetics shares are owned by company insiders. Comparatively, 7.6% of Femasys shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Neuronetics had 1 more articles in the media than Femasys. MarketBeat recorded 3 mentions for Neuronetics and 2 mentions for Femasys. Neuronetics' average media sentiment score of 1.42 beat Femasys' score of 0.00 indicating that Neuronetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neuronetics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Femasys	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Neuronetics and Femasys tied by winning 8 of the 16 factors compared between the two stocks.

How does Femasys compare to Spectral AI?

Spectral AI (NASDAQ:MDAI) and Femasys (NASDAQ:FEMY) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, media sentiment, analyst recommendations and dividends.

Spectral AI currently has a consensus target price of $3.00, indicating a potential upside of 11.94%. Femasys has a consensus target price of $5.33, indicating a potential upside of 1,117.66%. Given Femasys' stronger consensus rating and higher possible upside, analysts clearly believe Femasys is more favorable than Spectral AI.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spectral AI	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Femasys	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Spectral AI has a beta of 1.16, suggesting that its stock price is 16% more volatile than the broader market. Comparatively, Femasys has a beta of -2.26, suggesting that its stock price is 326% less volatile than the broader market.

In the previous week, Spectral AI had 4 more articles in the media than Femasys. MarketBeat recorded 6 mentions for Spectral AI and 2 mentions for Femasys. Spectral AI's average media sentiment score of 0.35 beat Femasys' score of 0.00 indicating that Spectral AI is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spectral AI	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Femasys	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

67.1% of Spectral AI shares are owned by institutional investors. Comparatively, 65.3% of Femasys shares are owned by institutional investors. 13.7% of Spectral AI shares are owned by insiders. Comparatively, 7.6% of Femasys shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Spectral AI has a net margin of -85.58% compared to Femasys' net margin of -521.97%. Spectral AI's return on equity of 0.00% beat Femasys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spectral AI	-85.58%	N/A	-72.97%
Femasys	-521.97%	-258.08%	-73.72%

Spectral AI has higher revenue and earnings than Femasys. Spectral AI is trading at a lower price-to-earnings ratio than Femasys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spectral AI	$19.65M	4.34	-$7.57M	-$0.53	N/A
Femasys	$2.29M	11.55	-$18.63M	-$0.27	N/A

Summary

Spectral AI beats Femasys on 10 of the 16 factors compared between the two stocks.

Get Femasys News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FEMY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FEMY vs. The Competition

Export

Metric	Femasys	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$26.45M	$3.37B	$6.46B	$12.34B
Dividend Yield	N/A	2.26%	2.76%	5.28%
P/E Ratio	-1.62	18.74	21.00	25.66
Price / Sales	11.55	323.98	562.18	86.31
Price / Cash	N/A	125.17	43.49	56.67
Price / Book	3.65	7.09	10.41	7.14
Net Income	-$18.63M	$24.45M	$3.57B	$335.98M
7 Day Performance	22.14%	6.38%	6.40%	4.11%
1 Month Performance	7.62%	2.43%	3.54%	2.52%
1 Year Performance	-57.88%	62.98%	34.14%	35.04%

Femasys Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FEMY Femasys	2.1398 of 5 stars	$0.44 flat	$5.33 +1,117.7%	-57.9%	$26.45M	$2.29M	N/A	30	Gap Down High Trading Volume
SLNO Soleno Therapeutics	3.4372 of 5 stars	$53.01 flat	$76.67 +44.6%	N/A	$2.76B	$190.40M	29.95	30	Analyst Upgrade High Trading Volume
SKIN Beauty Health	2.7628 of 5 stars	$0.65 +7.2%	$2.32 +257.5%	-57.3%	$84.11M	$300.80M	N/A	1,030	Gap Down
SPAI Safe Pro Group	3.1442 of 5 stars	$4.00 -3.4%	$10.00 +150.1%	+48.4%	$83.12M	$1.64M	N/A	11	Gap Up
STIM Neuronetics	3.6042 of 5 stars	$1.17 -1.3%	$3.00 +157.5%	-69.9%	$81.77M	$149.16M	N/A	180	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FEMY) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Femasys (FEMY) Competitors

FEMY vs. SLNO, SKIN, SPAI, STIM, and MDAI

How does Femasys compare to Soleno Therapeutics?

Summary

How does Femasys compare to Beauty Health?

Summary

How does Femasys compare to Safe Pro Group?

Summary

How does Femasys compare to Neuronetics?

Summary

How does Femasys compare to Spectral AI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FEMY vs. The Competition

Femasys Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Femasys (FEMY) Competitors

FEMY vs. SLNO, SKIN, SPAI, STIM, and MDAI

How does Femasys compare to Soleno Therapeutics?

Which has more volatility & risk, SLNO or FEMY?

Does the media prefer SLNO or FEMY?

Is SLNO or FEMY more profitable?

Do insiders and institutionals believe in SLNO or FEMY?

Do analysts recommend SLNO or FEMY?

Which has better valuation & earnings, SLNO or FEMY?

Summary

How does Femasys compare to Beauty Health?

Do analysts recommend FEMY or SKIN?

Does the media refer more to FEMY or SKIN?

Is FEMY or SKIN more profitable?

Do insiders & institutionals hold more shares of FEMY or SKIN?

Which has better valuation & earnings, FEMY or SKIN?

Which has more risk and volatility, FEMY or SKIN?

Summary

How does Femasys compare to Safe Pro Group?

Is SPAI or FEMY more profitable?

Do analysts rate SPAI or FEMY?

Do institutionals & insiders believe in SPAI or FEMY?

Which has stronger earnings and valuation, SPAI or FEMY?

Does the media prefer SPAI or FEMY?

Which has more volatility and risk, SPAI or FEMY?

Summary

How does Femasys compare to Neuronetics?

Which has more risk and volatility, STIM or FEMY?

Is STIM or FEMY more profitable?

Which has higher valuation & earnings, STIM or FEMY?

Do analysts recommend STIM or FEMY?

Do insiders & institutionals believe in STIM or FEMY?

Does the media favor STIM or FEMY?

Summary

How does Femasys compare to Spectral AI?

Do analysts prefer MDAI or FEMY?

Which has more volatility and risk, MDAI or FEMY?

Does the media favor MDAI or FEMY?

Do insiders and institutionals believe in MDAI or FEMY?

Is MDAI or FEMY more profitable?

Which has preferable valuation and earnings, MDAI or FEMY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FEMY vs. The Competition

Femasys Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools